Low-dose dexamethasone administration for 3 weeks favorably affects plasma HDL concentration and composition but does not affect very low-density lipoprotein kinetics

European Journal of Endocrinology

Volumn 167, Issue 2, 2012, Pages 217-223

  Wang, Xuewen ^a   Magkos, Faidon ^a   Patterson, Bruce W ^a   Reeds, Dominic N ^a   Kampelman, Janine ^a   Mittendorfer, Bettina ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B100; DEXAMETHASONE; FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BODY WEIGHT; DRUG EFFECT; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; INSULIN SENSITIVITY; ISOTOPE LABELING; LIPOPROTEIN BLOOD LEVEL; LIVER; LOW DRUG DOSE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PARTICLE SIZE; PRIORITY JOURNAL; SIDE EFFECT;

ADULT; ANTI-INFLAMMATORY AGENTS; CHOLESTEROL, HDL; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KINETICS; LIPOPROTEINS, VLDL; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OSMOLAR CONCENTRATION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84864329629     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-12-0180     Document Type: Article

References (49)

1. Walker BR. Glucocorticoids and cardiovascular disease. European Journal of Endocrinology 2007 157 545-559. (doi:10.1530/EJE-07-0455)
2. Anagnostis P, Athyros VG, Tziomalos K, Karagiannis A & Mikhailidis DP. Clinical review: the pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. Journal of Clinical Endocrinology and Metabolism 2009 94 2692-2701. (doi:10. 1210/jc.2009-0370)
3. Macfarlane DP, Forbes S & Walker BR. Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome. Journal of Endocrinology 2008 197 189-204. (doi:10.1677/JOE-08-0054)
4. Divertie GD, Jensen MD & Miles JM. Stimulation of lipolysis in humans by physiological hypercortisolemia. Diabetes 1991 40 1228-1232. (doi:10.2337/diabetes.40.10.1228)
5. Dinneen S, Alzaid A, Miles J & Rizza R. Metabolic effects of the nocturnal rise in cortisol on carbohydrate metabolism in normal humans. Journal of Clinical Investigation 1993 92 2283-2290. (doi:10.1172/JCI116832)
6. Abumrad NA & Klein S. Update on the pathophysiology of obesity. Current Opinion in Clinical Nutrition and Metabolic Care 2010 13 357-358. (doi:10.1097/MCO.0b013e32833ae702)
7. Arnaldi G, Scandali VM, Trementino L, Cardinaletti M, Appolloni G & Boscaro M. Pathophysiology of dyslipidemia in Cushing's syndrome. Neuroendocrinology 2010 92 (Suppl 1) 86-90. (doi:10.1159/000314213)
8. el-Shaboury AH & Hayes TM. Hyperlipidaemia in asthmatic patients receiving long-term steroid therapy. BMJ 1973 2 85-86. (doi:10.1136/bmj.2.5858. 85)
9. Choi HK & Seeger JD. Glucocorticoid use and serum lipid levels in US adults: the Third National Health and Nutrition Examination Survey. Arthritis and Rheumatism 2005 53 528-535. (doi:10.1002/art.21329)
10. Ettinger WH, Klinefelter HF & Kwiterovitch PO. Effect of short-term, low-dose corticosteroids on plasma lipoprotein lipids. Atherosclerosis 1987 63 167-172. (doi:10.1016/0021-9150 (87)90117-1)
11. Georgiadis AN, Papavasiliou EC, Lourida ES, Alamanos Y, Kostara C, Tselepis AD & Drosos AA. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment - a prospective, controlled study. Arthritis Research & Therapy 2006 8 R82. (doi:10.1186/ar1952)
12. Freedman MR, Horwitz BA & Stern JS. Effect of adrenalectomy and glucocorticoid replacement on development of obesity. American Journal of Physiology 1986 250 R595-R607.
13. Mantha L, Palacios E & Deshaies Y. Modulation of triglyceride metabolism by glucocorticoids in diet-induced obesity. American Journal of Physiology 1999 277 R455-R464.
14. Filipsson H, Monson JP, Koltowska-Haggstrom M, Mattsson A & Johannsson G. The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. Journal of Clinical Endocrinology and Metabolism 2006 91 3954-3961. (doi:10.1210/jc.2006-0524)
15. Metropolitan Life Insurance Company 1983 Metropolitan height and weight tables. Statistical Bulletin of the Metropolitan Life Insurance Company 1983 64 2-9.
16. Magkos F, Patterson BW & Mittendorfer B. Reproducibility of stable isotope-labeled tracer measures of VLDL-triglyceride and VLDL-apolipoprotein B-100 kinetics. Journal of Lipid Research 2007 48 1204-1211. (doi:10.1194/jlr.D600048-JLR200)
17. Mittendorfer B, Patterson BW & Klein S. Effect of weight loss on VLDL-triglyceride and apoB-100 kinetics in women with abdominal obesity. American Journal of Physiology. Endocrinology and Metabolism 2003 284 E549-E556. (doi:10.1152/ajpendo. 00379.2002)
18. Otvos JD, Jeyarajah EJ, Bennett DW & Krauss RM. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clinical Chemistry 1992 38 1632-1638.
19. Magkos F, Mohammed BS & Mittendorfer B. Effect of obesity on the plasma lipoprotein subclass profile in normoglycemic and normolipidemic men and women. International Journal of Obesity 2008 32 1655-1664. (doi:10.1038/ijo. 2008.164)
20. Patterson BW, Zhao G, Elias N, Hachey DL & Klein S. Validation of a new procedure to determine plasma fatty acid concentration and isotopic enrichment. Journal of Lipid Research 1999 40 2118-2124.
21. Patterson BW, Mittendorfer B, Elias N, Satyanarayana R & Klein S. Use of stable isotopically labeled tracers to measure very low density lipoprotein-triglyceride turnover. Journal of Lipid Research 2002 43 223-233.
22. Magkos F, Fabbrini E, Korenblat K, Okunade AL, Patterson BW & Klein S. Reproducibility of glucose, fatty acid and VLDL kinetics and multi-organ insulin sensitivity in obese subjects with nonalcoholic fatty liver disease. International Journal of Obesity 2011 35 1233-1240. (doi:10.1038/ijo.2010.265)
23. Mittendorfer B, Liem O, Patterson BW, Miles JM & Klein S. What does the measurement of whole-body fatty acid rate of appearance in plasma by using a fatty acid tracer really mean? Diabetes 2003 52 1641-1648. (doi:10.2337/ diabetes.52.7.1641)
24. Matsuda M & DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999 22 1462-1470. (doi:10.2337/diacare.22.9.1462)
25. Tripathy D, Almgren P, Tuomi T & Groop L. Contribution of insulin-stimulated glucose uptake and basal hepatic insulin sensitivity to surrogate measures of insulin sensitivity. Diabetes Care 2004 27 2204-2210. (doi:10.2337/diacare.27.9.2204)
26. Fabbrini E, Magkos F, Conte C, Mittendorfer B, Patterson BW, Okunade AL & Klein S. Validation of a novel index to assess insulin resistance of adipose tissue lipolytic activity in obese subjects. Journal of Lipid Research 2012 53 321-324. (doi:10.1194/jlr. D020321)
27. Basu R, Basu A, Grudzien M, Jung P, Jacobson P, Johnson M, Singh R, Sarr M & Rizza RA. Liver is the site of splanchnic cortisol production in obese nondiabetic humans. Diabetes 2009 58 39-45. (doi:10.2337/db08-1079)
28. Baudrand R, Carvajal CA, Riquelme A, Morales M, Solis N, Pizarro M, Escalona A, Boza C, Perez G, Dominguez A, Arrese M & Fardella CE. Overexpression of 11β-hydroxysteroid dehydrogenase type 1 in hepatic and visceral adipose tissue is associated with metabolic disorders in morbidly obese patients. Obesity Surgery 2010 20 77-83. (doi:10.1007/s11695-009-9937-0)
29. Walker BR & Andrew R. Tissue production of cortisol by 11β-hydroxysteroid dehydrogenase type 1 and metabolic disease. Annals of the New York Academy of Sciences 2006 1083 165-184. (doi:10.1196/annals.1367. 012)
30. Pivonello R, De Leo M, Vitale P, Cozzolino A, Simeoli C, De Martino MC, Lombardi G & Colao A. Pathophysiology of diabetes mellitus in Cushing's syndrome. Neuroendocrinology 2010 92 (Suppl 1) 77-81. (doi:10.1159/000314319)
31. Jensen MD, Caruso M, Heiling V & Miles JM. Insulin regulation of lipolysis in nondiabetic and IDDM subjects. Diabetes 1989 38 1595-1601. (doi:10.2337/diabetes.38.12.1595)
32. Prager R, Wallace P & Olefsky JM. In vivo kinetics of insulin action on peripheral glucose disposal and hepatic glucose output in normal and obese subjects. Journal of Clinical Investigation 1986 78 472-481. (doi:10.1172/JCI112599)
33. Nicod N, Giusti V, Besse C & Tappy L. Metabolic adaptations to dexamethasone-induced insulin resistance in healthy volunteers. Obesity Research 2003 11 625-631. (doi:10.1038/oby.2003.90)
34. Gravholt CH, Dall R, Christiansen JS, Moller N & Schmitz O. Preferential stimulation of abdominal subcutaneous lipolysis after prednisolone exposure in humans. Obesity Research 2002 10 774-781. (doi:10.1038/oby.2002.105)
35. Miyoshi H, Shulman GI, Peters EJ, Wolfe MH, Elahi D & Wolfe RR. Hormonal control of substrate cycling in humans. Journal of Clinical Investigation 1988 81 1545-1555. (doi:10.1172/JCI113487)
36. Dirlewanger M, Schneiter PH, Paquot N, Jequier E, Rey V & Tappy L. Effects of glucocorticoids on hepatic sensitivity to insulin and glucagon in man. Clinical Nutrition 2000 19 29-34. (doi:10. 1054/clnu.1999.0064)
37. Matsumoto K, Yamasaki H, Akazawa S, Sakamaki H, Ishibashi M, Abiru N, Uotani S, Matsuo H, Yamaguchi Y, Tokuyama K & Nagataki S. High-dose but not low-dose dexamethasone impairs glucose tolerance by inducing compensatory failure of pancreatic β-cells in normal men. Journal of Clinical Endocrinology and Metabolism 1996 81 2621-2626. (doi:10.1210/jc.81.7.2621)
38. Wajngot A, Giacca A, Grill V, Vranic M & Efendic S. The diabetogenic effects of glucocorticoids are more pronounced in low- than in high-insulin responders. PNAS 1992 89 6035-6039. (doi:10.1073/pnas.89.13.6035)
39. Taskinen MR, Nikkila EA, Pelkonen R & Sane T. Plasma lipoproteins, lipolytic enzymes, and very low density lipoprotein triglyceride turnover in Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 1983 57 619-626. (doi:10.1210/ jcem-57-3-619)
40. Garcia-Gomez C, Nolla JM, Valverde J, Narvaez J, Corbella E & Pinto X. High HDL-cholesterol in women with rheumatoid arthritis on low-dose glucocorticoid therapy. European Journal of Clinical Investigation 2008 38 686-692. (doi:10.1111/j.1365- 2362.2008.01994.x)
41. Salazar A, Mana J, Pinto X, Argimon JM, Hurtado I & Pujol R. Corticosteroid therapy increases HDL-cholesterol concentrations in patients with active sarcoidosis and hypoalphalipoproteinemia. Clinica Chimica Acta 2002 320 59-64. (doi:10.1016/S0009- 8981(02)00046-3)
42. Staels B, van Tol A, Chan L, Verhoeven G & Auwerx J. Variable effects of different corticosteroids on plasma lipids, apolipoproteins, and hepatic apolipoprotein mRNA levels in rats. Arteriosclerosis and Thrombosis 1991 11 760-769. (doi:10.1161/01.ATV.11. 3.760)
43. Fried SK, Russell CD, Grauso NL & Brolin RE. Lipoprotein lipase regulation by insulin and glucocorticoid in subcutaneous and omental adipose tissues of obese women and men. Journal of Clinical Investigation 1993 92 2191-2198. (doi:10.1172/ JCI116821)
44. Qi D, Pulinilkunnil T, An D, Ghosh S, Abrahani A, Pospisilik JA, Brownsey R, Wambolt R, Allard M & Rodrigues B. Single-dose dexamethasone induces whole-body insulin resistance and alters both cardiac fatty acid and carbohydrate metabolism. Diabetes 2004 53 1790-1797. (doi:10.2337/diabetes.53.7. 1790)
45. Bagdade JD, Yee E, Albers J & Pykalisto OJ. Glucocorticoids and triglyceride transport: effects on triglyceride secretion rates, lipoprotein lipase, and plasma lipoproteins in the rat. Metabolism 1976 25 533-542. (doi:10.1016/0026-0495(76)90007-X)
46. Magkos F. Basal very low-density lipoprotein metabolism in response to exercise: mechanisms of hypotriacylglycerolemia. Progress in Lipid Research 2009 48 171-190. (doi:10.1016/j. plipres.2009.02.003)
47. Duncan GE, Perri MG, Theriaque DW, Hutson AD, Eckel RH & Stacpoole PW. Exercise training, without weight loss, increases insulin sensitivity and post heparin plasma lipase activity in previously sedentary adults. Diabetes Care 2003 26 557-562. (doi:10.2337/diacare.26.3.557)
48. Wang X, Smith GI, Patterson BW, Reeds DN, Kampelman J, Magkos F & Mittendorfer B. Testosterone increases the muscle protein synthesis rate but does not affect very-low-density lipoprotein metabolism in obese premenopausal women. American Journal of Physiology. Endocrinology and Metabolism 2012 302 E740-E746. (doi:10.1152/ajpendo.00533.2011)
49. Magkos F, Patterson BW & Mittendorfer B. No effect of menstrual cycle phase on basal very-low-density lipoprotein triglyceride and apolipoprotein B-100 kinetics. American Journal of Physiology. Endocrinology and Metabolism 2006 291 E1243-E1249. (doi:10.1152/ajpendo.00246.2006)